Oncotarget

Research Papers:

Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of bladder cancer

Mingwei Chen _, Jianfa Li, Chengle Zhuang and Zhiming Cai

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:28176-28186. https://doi.org/10.18632/oncotarget.14945

Metrics: PDF 1413 views  |   HTML 2085 views  |   ?  


Abstract

Mingwei Chen1, Jianfa Li2, Chengle Zhuang3, Zhiming Cai2

1Department of Urology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu 322000, Zhejiang, China

2Shantou University Medical College, Shantou 515041, Guangdong, China

3Peking University Shenzhen Hospita, Shenzhen 518036, Guangdong, China

Correspondence to:

Mingwei Chen, email: chenmingwei2016@126.com

Keywords: ABHD11-AS1, bladder cancer, lncRNAs, proliferation, migration

Received: October 09, 2016    Accepted: January 10, 2017    Published: February 01, 2017

ABSTRACT

Bladder cancer is one of the most common urothelial tumors worldwide. While there are some progresses on early bladder cancer detection, patients’ mortalities have not been changed significantly. So it is important to get further understanding the mechanism involved in the development and progression of bladder cancer. Long non-coding RNAs play important regulatory roles in a variety of biological processes ranging from gene regulation, cellular differentiation to tumorigenesis. Previous literatures reported that lncRNA ABHD11 Antisense RNA 1 (ABHD11-AS1) (Organism: Homo sapiens) was highly expressed in gastric cancer. Inspired by these observations, we hypothesized that ABHD11-AS1 possibly plays an analogous role in human bladder cancer. We first found that ABHD11-AS1 was up-regulated in bladder cancer tissues and cell lines, and ABHD11-AS1 expression level was positively associated with clinicobiological features. Cell proliferation, cell migration and apoptosis were observed by silencing ABHD11-AS1 and overexpression ABHD11-AS1 caused contrary effects. Taken together, these data suggested that ABHD11-AS1 may be an oncogene and a therapeutic target in bladder cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14945